Biotheus Entered into a Research Collaboration and License Agreement with BioNTech to Discover Novel Therapies for Cancer
Shots:
- Biotheus will receive up front & will also be eligible for clinical, regulatory, and commercial milestones along with royalties, following option exercise on Biotheus' preclinical-stage bispecific Ab
- BioNTech gets an exclusive option globally to a preclinical-stage bispecific Ab and a clinical-stage mAb for cancer therapy & also gets an exclusive license to existing panels of VHH binders against multiple targets along with options to request Biotheus to generate new panels of VHH binders against targets nominated by BioNTech
- The collaboration will combine Biotheus’ expertise to discover innovative, transformative therapies for patients globally
Ref: PRNewswire | Image: BioNTech
Related News:- Biotheus Entered into a License and Collaboration Agreement with Hansoh Pharma for PM1080
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
